Recombinant TAS2R43 is synthesized using advanced platforms such as Magic™ Membrane Protein Production (Creative Biolabs) :
Expression Systems: Mammalian (e.g., HEK-293) and insect cell lines for proper post-translational modifications .
Purification: Affinity chromatography with tags (e.g., GST) and stabilization using lipid nanodiscs .
Validation: Functional assays (calcium imaging) confirm receptor activity .
Recombinant TAS2R43 responds to diverse agonists and antagonists:
W35S/H212R Variants: Reduce receptor activity by >90%, correlating with lower caffeine bitterness perception and altered coffee preference .
Population Diversity: Over 166 predicted functional variants exist, though most are rare (frequency <0.01) .
Gut Physiology: Mediates caffeine-induced gastric acid secretion via parietal cells .
Immune Modulation: Potential role in detecting bacterial quorum-sensing molecules .
Bitter Masking Agents: HED and structural analogs inhibit TAS2R43 to mitigate drug aftertastes .
Toxicity Screening: Detects aristolochic acid exposure, a carcinogenic contaminant .
Gustducin-coupled receptor involved in the detection of bitter compounds within the oral cavity and gastrointestinal tract. It signals through PLCB2 and the calcium-regulated cation channel TRPM5. Activated by the artificial sweeteners saccharin and acesulfame K. In airway epithelial cells, bitter compound binding increases intracellular calcium ion concentration and stimulates ciliary beat frequency. It may function as a chemosensory receptor in airway epithelial cells, facilitating the detection and removal of potentially harmful agents from the airways.